DFP-11207 is under clinical development by Delta-Fly Pharma and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DFP-11207’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DFP-11207 overview

DFP-11207 is under development for the treatment of solid tumors including esophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer and gallbladder cancer. It is administered orally as a capsule. It is 5-fluorouracil derivative. It targets thymidylate synthase enzyme.

Delta-Fly Pharma overview

Delta-Fly Pharma is a biopharmaceutical and healthcare company. The company discovers and develops anti-cancer agents. It’s product portfolio includes DFP-10917, for the treatment of myelogenous leukemia; DFP-14323, an anticancer drug candidate treating lung cancer; DFP-10825, liposome-conjugated RNAi molecule which targets disseminated ovarian and gastric cancer. Delta-Fly Pharma also develops DFP-11207, cancer cell metabolism regulator that treats stomach cancer; DFP-14927, Polymeric anti-cancer agent for the treatment of solid tumors. The company develops novel products using module technology (Module Drug Discovery). It has its operations in Japan, Canada, and China. Delta-Fly Pharma is headquartered in Tokushima-Shi, Tokushima, Japan.

For a complete picture of DFP-11207’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.